Oxaliplatin/Fluorouracil/Leucovorin in Advanced Colorectal Carcinoma: An Asian Experience

Annals of Pharmacotherapy

Volumn 37, Issue 12, 2003, Pages 1909-1912

  Lim, Elaine Hsuen ^a   Lim, Robert Seng Cheong ^a   Wu, Tuck Seng ^a   Kong, Hwai Loong ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Asian; Colorectal carcinoma; Hypersensitivity; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; CLINICAL TRIAL; COLORECTAL CARCINOMA; EDEMA; EVALUATION; HUMAN; HYPERSENSITIVITY; PARESTHESIA; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; URTICARIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 0344412960     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D153     Document Type: Article

References (18)

1. Chia KS, Seow A, Lee HP, Shanmugaratnam K. Cancer incidence in Singapore 1993-1997. Singapore Cancer Registry report no. 5, 2000:78-81.
2. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. volume VII, 1997. IARC Scientific Publications no. 143.
3. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18.
4. Saltz LB, Cox JV, Blanke C, Lee SR, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
6. Rothenberg ML, Meropol NJ, Poplin EA, van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-7.
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
8. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
9. Goh BC, Lehnert ML, Lim HL, Ng AW, Chan CC, Kong HL, et al. Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer. Acta Oncol 2000;39:225-9.
10. Wood AJJ. Racial differences in the response to drugs - pointers to genetic differences. N Engl J Med 2001;344:1393.
11. National Cancer Institute common toxicity criteria grading system, version 2.0. ctep.cancer.gov/reporting/ctc.html (accessed 2003 October 8).
12. Graham MA, Lockwood GF, Greenslade D, Brinza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000;6:1205-18.
13. Tournigand C, Maindrault-Goebel F, Louvet C, de Gramont A, Krulik M. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer 1998;34:1297-8.
14. Larzilliere I, Brandissou S, Breton P, Lingoungou A, Gargot D, Ramain JP, et al. Anaphylactic reaction to oxaliplatin: a case report. Am J Gastroenterol 1999;94:3387-8.
15. Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL. Anaphylaxis after oxaliplatin (letter). Ann Oncol 1999;10:610.
16. Dold F, Hoey D, Carberry M, Musket A, Friedberg V, Mitchell E. Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin (abstract 1478). In: Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 17-21, 2002.
17. de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9.
18. Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-8.